Breast Cancer | Clinical

FDA Okays Guardant360 Test as CDx for Elacestrant in ESR1-mutated Breast Cancer

January 30, 2023

The Guardant360 CDx, which will identify patients with advanced or metastatic breast cancer who have ESR1 mutations and may benefit from elacestrant, is the fifth test to be approved by the FDA and first for patients with breast cancer.

Next Steps for Trastuzumab Emtansine After the KAMILLA Trial

January 23, 2023

Rachel Würstlein, MD, discusses the use of trastuzumab emtansine following the KAMILLA trial which evaluated the agent in patients with HER2-positive locally advanced or metastatic breast cancer who have brain metastases.

RWD Show Survival Advantage of Frontline Letrozole Plus Palbociclib in Minorities With aBC

January 18, 2023

Adam Brufsky, MD, PhD, FACP, discusses the real-world efficacy of letrozole in combination with palbociclib as treatment of patients with estrogen receptor-positive, HER2-negative, advanced breast cancer, based on race and ethnicity.